Piceatannol 是一种Syk抑制剂，可降低由 TNF 诱导的 iNOS 表达。 Piceatannol 可用于急性肺损伤 (ALI)的研究。Piceatannol 是一种天然存在的多酚二苯乙烯，存在于各种水果和蔬菜中，具有抗癌和抗炎特性。Piceatannol 在 DLBCL 细胞系中诱导细胞凋亡(apoptosis)。Piceatannol 在 MOLT-4 人白血病细胞中诱导自噬 (autophagy) 和凋亡 (apoptosis)。
| 生物活性 | Piceatannol is a well-knownSykinhibitor and reduces the expression ofiNOSinduced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol inducesapoptosisin DLBCL cell lines[3]. Piceatannol inducesautophagyandapoptosisin MOLT-4 human leukemia cells[4]. |
体外研究
(In Vitro) | Piceatannol is a resveratrol metabolite[2].
SYK inhibitor Piceatannol (3.125, 6.25, 12.5, 25, and 50 μM; 72 hours) inhibits cell growth of six diffuse large B cell lymphomas (DLBCL) cell lines (SUDHL-6, U2392,DOHH2,Karpas 422, VAL, OCI Ly19) with IC50s of 18 μM, 25 μM, 37 μM, 48 μM, >50 μM and >50 μM, respectively[3].
Cell Cytotoxicity Assay[3] | Cell Line: | Six DLBCL cell lines (Karpas 422, VAL, SUDHL-6, OCI Ly19, U2392 and DOHH2) | | Concentration: | 3.125, 6.25, 12.5, 25, and 50 μM | | Incubation Time: | 72 hours | | Result: | The IC50s were 18 μM in SUDHL-6, 25 μM in U2392, 37 mM in DOHH2, 48 μM in Karpas 422 and higher than 50 μM in OCI-Ly19 and in VAL. |
|
体内研究
(In Vivo) | Piceatannol (10, 20, and 40 mg/kg) inhibits the pulmonary edema and reduces the infiltration of inflammatory cells induced by lipopolysaccharide[1].
Piceatannol (10, 20, and 40 mg/kg) alleviates the myeloperoxidase activity and inhibits the production of iNOS and COX-2 expressions in lung tissuesinduced by lipopolysaccharide[1].
Piceatannol (10, 20, and 40 mg/kg; intraperitoneally 1 h) treatment alleviates inflammatory response by inhibiting the activation of TLR/NF-κB signaling pathway in lung tissues during acute lung injury (ALI) induced by LPS[1].
| Animal Model: | Male C57BL/6 mice (40-50 g)[1] | | Dosage: | 10, 20, and 40 mg/kg | | Administration: | Intraperitoneally 1 h before LPS challenge | | Result: | Significantly reduced the pulmonary edema induced by LPS. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Polygonaceae
- Rheum palmatumL.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : ≥ 31 mg/mL(126.92 mM) H2O : 1 mg/mL(4.09 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 4.0943 mL | 20.4717 mL | 40.9433 mL | | 5 mM | 0.8189 mL | 4.0943 mL | 8.1887 mL | | 10 mM | 0.4094 mL | 2.0472 mL | 4.0943 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.24 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.24 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com